This company is no longer active
ZSAN.Q Stock Overview
Zosano Pharma Corporation, a clinical stage biopharmaceutical company, focuses on providing therapeutics and other bioactive molecules to patients suffering from migraine using its transdermal microneedle system.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Zosano Pharma Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.0007 |
| 52 Week High | US$24.80 |
| 52 Week Low | US$0.0001 |
| Beta | 2.73 |
| 1 Month Change | 133.33% |
| 3 Month Change | -99.45% |
| 1 Year Change | -100.00% |
| 3 Year Change | -100.00% |
| 5 Year Change | -100.00% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Can Zosano Pharma (NASDAQ:ZSAN) Afford To Invest In Growth?
Nov 02
Is Zosano Pharma (NASDAQ:ZSAN) Weighed On By Its Debt Load?
Jun 29Data supports long-term benefit of Zosano's migraine candidate; shares surge 23%
May 26Zosano Pharma: Early PK+Safety Study In Q3 2021 May Breathe New Life Into This Biotech
Apr 30Zosano shares rise on migraine treatment NDA resubmission update
Apr 26Auditors Have Doubts About Zosano Pharma (NASDAQ:ZSAN)
Mar 15Zosano Pharma up 21% following FDA feedback on Qtrypta application; presents Qtrypta data in migraine
Feb 01Zosano Pharma requests FDA meeting for its Qtrypta application
Jan 04Zosano Pharma EPS misses by $0.01
Nov 13Shareholder Returns
| ZSAN.Q | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 40.0% | -2.9% | -3.2% |
| 1Y | -100.0% | -3.7% | 19.3% |
Return vs Industry: ZSAN.Q underperformed the US Medical Equipment industry which returned -22.2% over the past year.
Return vs Market: ZSAN.Q underperformed the US Market which returned -20.2% over the past year.
Price Volatility
| ZSAN.Q volatility | |
|---|---|
| ZSAN.Q Average Weekly Movement | 4,827.6% |
| Medical Equipment Industry Average Movement | 7.4% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: ZSAN.Q's share price has been volatile over the past 3 months.
Volatility Over Time: ZSAN.Q's weekly volatility has increased from 2395% to 4789% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 40 | Steven Lo | www.zosanopharma.com |
Zosano Pharma Corporation, a clinical stage biopharmaceutical company, focuses on providing therapeutics and other bioactive molecules to patients suffering from migraine using its transdermal microneedle system. Its lead product candidate is Qtrypta (M207), a proprietary formulation of zolmitriptan used for the acute treatment of migraine. The company was founded in 2006 and is headquartered in Fremont, California.
Zosano Pharma Corporation Fundamentals Summary
| ZSAN.Q fundamental statistics | |
|---|---|
| Market cap | US$3.43k |
| Earnings (TTM) | -US$55.19m |
| Revenue (TTM) | US$659.00k |
0.0x
P/S Ratio0.0x
P/E RatioIs ZSAN.Q overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ZSAN.Q income statement (TTM) | |
|---|---|
| Revenue | US$659.00k |
| Cost of Revenue | US$20.85m |
| Gross Profit | -US$20.19m |
| Other Expenses | US$35.01m |
| Earnings | -US$55.19m |
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -11.26 |
| Gross Margin | -3,063.13% |
| Net Profit Margin | -8,375.11% |
| Debt/Equity Ratio | 0% |
How did ZSAN.Q perform over the long term?
See historical performance and comparison